Table 3:
Recent siRNA applications for drug delivery in rodent models of OA
| Target | Delivery route | Carrier | Analysis time point | Outcome | Model | Reference |
|---|---|---|---|---|---|---|
| Ihh | IA | Lipid nanoparticle | 10 weeks | Chondroprotective; attenuated cartilage degeneration | Rat ACLT | [93] |
| NF-κB | IA | Peptide (p5RHH) | 2 weeks | Reduced synovitis; reduced chondrocyte apoptosis | Mouse joint loading | [96] |
| Yap | IA | None | 8 weeks | Ameliorated OA development; reduced aberrant bone formation; prevented cartilage degradation | Mouse ACLT | [97] |
| Hif-2α | IA | Chondrocyte-homing peptide/PEI | 7 weeks | Reduced cartilage degeneration; Alleviated synovitis | Mouse ACLT, MCLT | [99] |
| MMP-13 ADAMTS-5 | IA | None | 4, 8 weeks | Reduced cartilage degeneration; lowered OA score | DMM | [101] |
| MMP-13 | IA | None | 8 weeks | Reduced OARSI score; delayed cartilage degeneration | DMM | [102] |
| MMP-13 | IA | None | 2 weeks | Reduce cartilage degeneration; decreased OARSI score | DMM | [103] |
ACLT = anterior cruciate ligament transection/tear; IA = intra-articular; MCLT = medial collateral ligament transection; DMM = destabilization of medial meniscus; OARSI = Osteoarthritis Research Society International